Test case for Herceptin to decide if UK health providers can refuse breast cancer drug treatment
A test case at the High Court in the UK is due to determine whether a health authority has the right to refuse to fund a cancer treatment, which has been prescribed by a phy-sician, and which has been recommended by the country's Secretary of State for Health. After two days of hearings ending February 7, the judge has reserved judgement for a week, citing the urgency of the case for the patient.
Ann Marie Rogers, a 54 year old from Swindon, UK borrowed L5,000.0 ($8752.5) to pay for Swiss-based drug maker Roche's Herceptin (trastuzumab), because Swindon Primary Care Trust refuses to pay for the treat-ment, in what the plaintiff argues is in defiance of the UK government's guidelines. Previous legal challenges have been resolved by the health care provider backing down.
Waiting for NICE to decide
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze